Conformationally restricted analogues of the potent CCK-B antagonist CI-988
The synthesis and structure-activity relationships (SAR) for a series of conformationally restricted analogues of the selective cholecystokinin (CCK) antagonist CI-988 are described.
References (20)
- et al.
Trends in Pharm. Sci.
(1990) - et al.
BioMed. Chem. Lett.
(1993) Life Sci.
(1982)- et al.
BioMed. Chem. Lett.
(1991) Med. Res. Rev.
(1989)Drugs of the Future
(1991)- et al.
Ann. Rev. Pharmacol. Toxicol.
(1991) Drugs of the Future
(1991)- et al.
J. Med. Chem.
(1991) - et al.
J. Med. Chem.
(1993)
There are more references available in the full text version of this article.
Cited by (10)
CCK-B receptor: Chemistry, molecular biology, biochemistry and pharmacology
1999, Progress in NeurobiologyHighly constrained dipeptoid analogues containing a type II' β-turn mimic as novel and selective CCK-A receptor ligands
1999, Bioorganic and Medicinal Chemistry LettersPharmacology of CCKRs and SAR studies of peptidic analog ligands
2007, Current Topics in Medicinal Chemistry"Dipeptoids": From the chemical structure of the endogenous peptide to the design of peptidomimetics
2004, Mini-Reviews in Medicinal ChemistryCholecystokinin antagonists: Pharmacological and therapeutic potential
2003, Medicinal Research Reviewsβ-Turned dipeptoids as potent and selective CCK<inf>1</inf> receptor antagonists
2000, Journal of Medicinal Chemistry
Copyright © 1993 Published by Elsevier Ltd.